Materiały źródłowe

• #1 Astrocytoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559042/

  Understanding epidemiological patterns for astrocytoma is important for identifying risk factors and improving early detection across various populations and age groups. […] Minimal racial differences have been found. […] There appears to be no gender dominance in pilocytic astrocytomas. Study results have demonstrated a man-to-woman ratio of 1.18:1 in low-grade astrocytomas. In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as 1.87:1. […] The likelihood of pilocytic astrocytoma increases during the first 2 decades of life. Low-grade astrocytomas are predominant in individuals aged 30 to 40, comprising about one-fourth of adult cases. The age distribution of patients with low-grade astrocytomas is as follows: 10%: younger than 20, 60%: 20 to 45 years, 30%: older than 45 years. For grade 3 astrocytoma, the mean age at diagnosis is approximately 40 years.

• #2 Astrocytoma | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/17930

  Astrocytomas represent a significant and complex subset of brain tumors originating from astrocytes, the star-shaped glial cells that play a critical role in supporting neuronal function within the cerebrum. […] These tumors present a considerable clinical challenge due to their prevalence and the serious morbidity and mortality they cause across all age groups. […] Understanding epidemiological patterns for astrocytoma is important for identifying risk factors and improving early detection across various populations and age groups. […] Minimal racial differences have been found. […] There appears to be no gender dominance in pilocytic astrocytomas. […] Study results have demonstrated a man-to-woman ratio of 1.18:1 in low-grade astrocytomas. […] In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as 1.87:1.

• #3 Astrocytoma – Diagnosis & Disease Information for HCPs

  https://www.cancertherapyadvisor.com/ddi/astrocytoma/

  In the United States, approximately 15,000 new cases of astrocytoma are diagnosed every year, accounting for roughly 50% of all brain tumors. The incidence of astrocytoma varies with the grade: grades I and II are less common, while high grades such as glioblastoma (grade IV) have a higher incidence and are associated with a worse prognosis. Astrocytoma tumors are slightly more common in males than in females. Higher-grade neoplasms are more common in adult patients, while low-grade forms occur more often in pediatric patients. […] The etiology of astrocytoma is complex; both genetic and environmental factors have a role in its pathogenesis. […] Risk factors for astrocytoma include the following: Occupational exposures to chemicals such as petrochemicals, formaldehyde, and polyvinyl chloride; Prolonged exposures to electromagnetic fields; and Exposure to pesticides and herbicides.

• #4 Astrocytoma – Diagnosis & Disease Information for HCPs

  https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/pediatrics/high-grade-astrocytomas/

  In the United States, approximately 15,000 new cases of astrocytoma are diagnosed every year, accounting for roughly 50% of all brain tumors. The incidence of astrocytoma varies with the grade: grades I and II are less common, while high grades such as glioblastoma (grade IV) have a higher incidence and are associated with a worse prognosis. Astrocytoma tumors are slightly more common in males than in females. Higher-grade neoplasms are more common in adult patients, while low-grade forms occur more often in pediatric patients. […] The etiology of astrocytoma is complex; both genetic and environmental factors have a role in its pathogenesis. […] Some of the environmental factors being investigated in relation to astrocytoma risk include occupational exposures to certain industrial chemicals, electromagnetic fields, pesticides, and certain dietary elements. […] Risk factors for astrocytoma include the following: Occupational exposures to chemicals such as petrochemicals, formaldehyde, and polyvinyl chloride; Prolonged exposures to electromagnetic fields; and Exposure to pesticides and herbicides.

• #5 Astrocytoma (Adult-type) – American Brain Tumor Association | Learn More

  https://www.abta.org/tumor_types/astrocytoma/

  Astrocytomas are estimated to account for 3.5% of all primary brain tumors with approximately 1,500 new diagnoses in the United States each year. […] Diffuse astrocytomas most often occur between the ages of 20-60 with a median age at diagnosis of 46 years for lower grade lesions and 54 years for higher grade lesions. […] Although these tumors are found in both men and women, they tend to occur more often in men. […] Regular MRI scans are recommended following the diagnosis of astrocytoma, generally at least once per year.

• #6 Astrocytoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Astrocytoma_epidemiology_and_demographics

  The incidence of astrocytoma is 0.23 per 100,000 and the number of new cases is 700 per year. […] In 2012, there were an estimated 148,818 people living with brain and other nervous system cancer in the United States. […] The number of deaths was 4.3 per 100,000 individuals per year based on 2008-2012 mortality records. […] The low-grade type is often found in children or young adults, while the high-grade type is more prevalent in adults. […] Pilocytic astrocytoma is more common in men, who account for 62% of all cases. […] The male-to-female ratio of diffuse astrocytoma is 1.5:1 and for anaplastic astrocytoma is 1.8:1. […] Astrocytoma is more common in caucasian race. […] Diffuse astrocytoma has an incidence of 0.1 per 100,000, with 1500 to 1800 new cases per year in North America.

• #7 Astrocytoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Astrocytoma_epidemiology_and_demographics

  Anaplastic astrocytoma has an incidence of 0.49 per 100,000 per year. […] Glioblastoma has an incidence of 5 per 100,000 per year. […] Pilocytic astrocytoma accounts for 0.6 – 5.1% of all intracranial neoplasms (1.7-7% of all glial tumors) and are the most common primary brain tumor of childhood, accounting for 70-85% of all cerebellar astrocytomas. […] The median age of diffuse astrocytoma at the time of the diagnosis is 35 years, with a bimodal age distribution at 6 to 12 years and 26 to 46 years. […] Diffuse low grade gliomas of the cerebral hemispheres are typically diagnosed in young adults between 20-45 years old (mean 35 years of age). […] The peak incidence of glioblastoma is at ages 65 to 74 years.

• #8 Low-Grade Astrocytoma: Background, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1156429-overview

  A study of the incidence of brain tumors in Europe concluded that of all glial tumors, the astrocytic subtype is the most common with a reported incidence of 4.8 cases per 100,000 people per year. […] Five-year survival after diagnosis of a non-malignant CNS tumor is 91.9%. […] However, due to the inherent differences in biology and natural history of this heterogeneous patient population, it is difficult to determine an exact mortality rate for low-grade astrocytomas. […] Pilocytic tumors can potentially be cured with surgical resection, and in specific cases where resection is not amenable, these can be treated with BRAF inhibitors. […] Although survival is affected by some prognostic factors, average overall survival from diagnosis is about 56 years, ranging from 3 to 10 years. […] For primary tumors in the CNS, there is a slight increase in incidence in non-Hispanic patients (25.24 per 100,000 patients) compared to Hispanic patients (22.61 per 100,000 patients).

• #9 Low-Grade Astrocytoma: Background, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1156429-overview

  The overall incidence of all primary malignant and non-malignant brain and other CNS tumors is 24.83 cases per 100,000 people (6.94 per 100,000 for malignant tumors and 17.88 per 100,000 for non-malignant tumors). […] Of all glioma subtypes, diffuse astrocytomas represent 9.1% and pilocytic astrocytomas 5.1%. […] Although these numbers represent an approximate estimation of the epidemiology of low-grade astrocytomas, it is important to note that there are no studies that have addressed this group in an isolated fashion. […] Gliomas can be found more frequently in patients with certain phakomatoses, especially neurofibromatosis type 1 (NF-1). Low-grade astrocytomas occur more commonly in these patients, particularly in the optic nerves and optic chiasm. […] The incidence of low-grade astrocytomas has not been shown to vary significantly by nationality.

• #10 Astrocytoma Tumors – AANS

  https://www.aans.org/patients/conditions-treatments/astrocytoma-tumors/

  Astrocytomas are tumors which originates from astrocytes, and, in adult individuals, they are the most common brain tumors. In the US, about 15,000 new astrocytomas are diagnosed every year. Males are slightly more affected than females, with a ratio of 1.3/1. […] Astrocytomas are, for the vast majority, sporadic tumors, meaning that they happen by chance, or at least, it is not yet known why these occur. There are only two situations with proven evidence to cause the tumor: […] The major factors determining length of survival after a diagnosis of astrocytoma are the following: […] Grade 1 tumors are largely cured (96% survival rate at 5 years), usually by surgery only. […] Grade 2 tumors: Overall median survival is 8 years. Presence of IDH1 mutation is associated with longer survival. […] Grade 3 tumors: Median survival is 3-5 years […] Grade 4 tumors: Median survival is 15 months.

• #11 Astrocytoma (Adult-type) – American Brain Tumor Association | Learn More

  https://www.abta.org/tumor_types/astrocytoma/

  Astrocytomas are estimated to account for 3.5% of all primary brain tumors with approximately 1,500 new diagnoses in the United States each year. […] Diffuse astrocytomas most often occur between the ages of 20-60 with a median age at diagnosis of 46 years for lower grade lesions and 54 years for higher grade lesions. […] Although these tumors are found in both men and women, they tend to occur more often in men. […] Regular MRI scans are recommended following the diagnosis of astrocytoma, generally at least once per year.

• #12 Astrocytoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Astrocytoma_epidemiology_and_demographics

  The incidence of astrocytoma is 0.23 per 100,000 and the number of new cases is 700 per year. […] In 2012, there were an estimated 148,818 people living with brain and other nervous system cancer in the United States. […] The number of deaths was 4.3 per 100,000 individuals per year based on 2008-2012 mortality records. […] The low-grade type is often found in children or young adults, while the high-grade type is more prevalent in adults. […] Pilocytic astrocytoma is more common in men, who account for 62% of all cases. […] The male-to-female ratio of diffuse astrocytoma is 1.5:1 and for anaplastic astrocytoma is 1.8:1. […] Astrocytoma is more common in caucasian race. […] Diffuse astrocytoma has an incidence of 0.1 per 100,000, with 1500 to 1800 new cases per year in North America.

• #13 Astrocytoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559042/

  Understanding epidemiological patterns for astrocytoma is important for identifying risk factors and improving early detection across various populations and age groups. […] Minimal racial differences have been found. […] There appears to be no gender dominance in pilocytic astrocytomas. Study results have demonstrated a man-to-woman ratio of 1.18:1 in low-grade astrocytomas. In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as 1.87:1. […] The likelihood of pilocytic astrocytoma increases during the first 2 decades of life. Low-grade astrocytomas are predominant in individuals aged 30 to 40, comprising about one-fourth of adult cases. The age distribution of patients with low-grade astrocytomas is as follows: 10%: younger than 20, 60%: 20 to 45 years, 30%: older than 45 years. For grade 3 astrocytoma, the mean age at diagnosis is approximately 40 years.

• #14 Astrocytoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Astrocytoma_epidemiology_and_demographics

  The incidence of astrocytoma is 0.23 per 100,000 and the number of new cases is 700 per year. […] In 2012, there were an estimated 148,818 people living with brain and other nervous system cancer in the United States. […] The number of deaths was 4.3 per 100,000 individuals per year based on 2008-2012 mortality records. […] The low-grade type is often found in children or young adults, while the high-grade type is more prevalent in adults. […] Pilocytic astrocytoma is more common in men, who account for 62% of all cases. […] The male-to-female ratio of diffuse astrocytoma is 1.5:1 and for anaplastic astrocytoma is 1.8:1. […] Astrocytoma is more common in caucasian race. […] Diffuse astrocytoma has an incidence of 0.1 per 100,000, with 1500 to 1800 new cases per year in North America.

• #15 Astrocytoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559042/

  Understanding epidemiological patterns for astrocytoma is important for identifying risk factors and improving early detection across various populations and age groups. […] Minimal racial differences have been found. […] There appears to be no gender dominance in pilocytic astrocytomas. Study results have demonstrated a man-to-woman ratio of 1.18:1 in low-grade astrocytomas. In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as 1.87:1. […] The likelihood of pilocytic astrocytoma increases during the first 2 decades of life. Low-grade astrocytomas are predominant in individuals aged 30 to 40, comprising about one-fourth of adult cases. The age distribution of patients with low-grade astrocytomas is as follows: 10%: younger than 20, 60%: 20 to 45 years, 30%: older than 45 years. For grade 3 astrocytoma, the mean age at diagnosis is approximately 40 years.

• #16 Astrocytoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/283453-overview

  The American Cancer Society estimates that in 2024, approximately 25,400 malignant tumors of the brain or spinal cord will be diagnosed, and about 18,760 deaths will occur from those tumors. […] The annual incidence of glioma in the United States is 6.0 cases per 100,000 population. […] In an analysis of the Central Brain Tumor Registry of the United States (CBTRUS) from 2019, 19% of all adult-type diffuse gliomas were IDH1-mutant astrocytomas. […] While increasing age has been shown to be a very strong risk factor for the development of glioblastoma, IDH1-mutant gliomas tend to affect a younger population. […] In the United States, the incidence of adult-type diffuse glioma is the highest in the non-Hispanic White population. […] A slight male predominance, with a male-to-female ratio of 1.18:1, has been reported for development of lower-grade astrocytomas. […] A more significant male predominance, with a male-to-female ratio of 1.87:1, has been reported for the development of higher-grade astrocytomas.

• #17 Astrocytoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Astrocytoma_epidemiology_and_demographics

  The incidence of astrocytoma is 0.23 per 100,000 and the number of new cases is 700 per year. […] In 2012, there were an estimated 148,818 people living with brain and other nervous system cancer in the United States. […] The number of deaths was 4.3 per 100,000 individuals per year based on 2008-2012 mortality records. […] The low-grade type is often found in children or young adults, while the high-grade type is more prevalent in adults. […] Pilocytic astrocytoma is more common in men, who account for 62% of all cases. […] The male-to-female ratio of diffuse astrocytoma is 1.5:1 and for anaplastic astrocytoma is 1.8:1. […] Astrocytoma is more common in caucasian race. […] Diffuse astrocytoma has an incidence of 0.1 per 100,000, with 1500 to 1800 new cases per year in North America.

• #18 Astrocytoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559042/

  Understanding epidemiological patterns for astrocytoma is important for identifying risk factors and improving early detection across various populations and age groups. […] Minimal racial differences have been found. […] There appears to be no gender dominance in pilocytic astrocytomas. Study results have demonstrated a man-to-woman ratio of 1.18:1 in low-grade astrocytomas. In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as 1.87:1. […] The likelihood of pilocytic astrocytoma increases during the first 2 decades of life. Low-grade astrocytomas are predominant in individuals aged 30 to 40, comprising about one-fourth of adult cases. The age distribution of patients with low-grade astrocytomas is as follows: 10%: younger than 20, 60%: 20 to 45 years, 30%: older than 45 years. For grade 3 astrocytoma, the mean age at diagnosis is approximately 40 years.

• #19 Astrocytoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/283453-overview

  The American Cancer Society estimates that in 2024, approximately 25,400 malignant tumors of the brain or spinal cord will be diagnosed, and about 18,760 deaths will occur from those tumors. […] The annual incidence of glioma in the United States is 6.0 cases per 100,000 population. […] In an analysis of the Central Brain Tumor Registry of the United States (CBTRUS) from 2019, 19% of all adult-type diffuse gliomas were IDH1-mutant astrocytomas. […] While increasing age has been shown to be a very strong risk factor for the development of glioblastoma, IDH1-mutant gliomas tend to affect a younger population. […] In the United States, the incidence of adult-type diffuse glioma is the highest in the non-Hispanic White population. […] A slight male predominance, with a male-to-female ratio of 1.18:1, has been reported for development of lower-grade astrocytomas. […] A more significant male predominance, with a male-to-female ratio of 1.87:1, has been reported for the development of higher-grade astrocytomas.

• #20 Astrocytoma, IDH-mutant | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/astrocytoma-idh-mutant-1?lang=us

  IDH-mutant adult-type astrocytomas are typically diagnosed in young adults (median age of 36 years for grades 2 and 3 (combined), and 38 years for grade 4). This is substantially younger than glioblastoma IDH-wildtype tumors (median 50-60 years of age). […] There is a substantially higher incidence in men of all ages and of all grades tumor (M:F ~1.5).

• #21 Astrocytoma – Diagnosis & Disease Information for HCPs

  https://www.cancertherapyadvisor.com/ddi/astrocytoma/

  In the United States, approximately 15,000 new cases of astrocytoma are diagnosed every year, accounting for roughly 50% of all brain tumors. The incidence of astrocytoma varies with the grade: grades I and II are less common, while high grades such as glioblastoma (grade IV) have a higher incidence and are associated with a worse prognosis. Astrocytoma tumors are slightly more common in males than in females. Higher-grade neoplasms are more common in adult patients, while low-grade forms occur more often in pediatric patients. […] The etiology of astrocytoma is complex; both genetic and environmental factors have a role in its pathogenesis. […] Risk factors for astrocytoma include the following: Occupational exposures to chemicals such as petrochemicals, formaldehyde, and polyvinyl chloride; Prolonged exposures to electromagnetic fields; and Exposure to pesticides and herbicides.

• #22 Astrocytoma – Diagnosis & Disease Information for HCPs

  https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/pediatrics/high-grade-astrocytomas/

  In the United States, approximately 15,000 new cases of astrocytoma are diagnosed every year, accounting for roughly 50% of all brain tumors. The incidence of astrocytoma varies with the grade: grades I and II are less common, while high grades such as glioblastoma (grade IV) have a higher incidence and are associated with a worse prognosis. Astrocytoma tumors are slightly more common in males than in females. Higher-grade neoplasms are more common in adult patients, while low-grade forms occur more often in pediatric patients. […] The etiology of astrocytoma is complex; both genetic and environmental factors have a role in its pathogenesis. […] Some of the environmental factors being investigated in relation to astrocytoma risk include occupational exposures to certain industrial chemicals, electromagnetic fields, pesticides, and certain dietary elements. […] Risk factors for astrocytoma include the following: Occupational exposures to chemicals such as petrochemicals, formaldehyde, and polyvinyl chloride; Prolonged exposures to electromagnetic fields; and Exposure to pesticides and herbicides.

• #23 Pilocytic astrocytoma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/pilocytic-astrocytoma?lang=us

  Pilocytic astrocytomas are tumors of young people, with ~70% occurring in the first two decades of life, typically late in the first decade (9-10 years). […] Although they account for ~2.5% (range 0.6-5.1%) of all intracranial neoplasms (~4% of all glial tumors), they are the most common primary brain tumor of childhood (~15%) and the second most common pediatric posterior fossa tumor (~30%) after medulloblastomas. […] There is a strong association with NF1. NF1-associated tumors have a tendency to affect the optic nerves and chiasm (see: optic pathway glioma). The association between NF1 and pilocytic astrocytomas is so strong that up to 20% of all patients with NF1 will develop these tumors, typically in early childhood. Conversely, approximately one-third of pilocytic astrocytomas involving the optic nerves have associated NF1. […] Adults have a poorer prognosis, with a ~50% 5-year survival.

• #24 Astrocytoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Astrocytoma_epidemiology_and_demographics

  Anaplastic astrocytoma has an incidence of 0.49 per 100,000 per year. […] Glioblastoma has an incidence of 5 per 100,000 per year. […] Pilocytic astrocytoma accounts for 0.6 – 5.1% of all intracranial neoplasms (1.7-7% of all glial tumors) and are the most common primary brain tumor of childhood, accounting for 70-85% of all cerebellar astrocytomas. […] The median age of diffuse astrocytoma at the time of the diagnosis is 35 years, with a bimodal age distribution at 6 to 12 years and 26 to 46 years. […] Diffuse low grade gliomas of the cerebral hemispheres are typically diagnosed in young adults between 20-45 years old (mean 35 years of age). […] The peak incidence of glioblastoma is at ages 65 to 74 years.

• #25 Astrocytoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559042/

  Understanding epidemiological patterns for astrocytoma is important for identifying risk factors and improving early detection across various populations and age groups. […] Minimal racial differences have been found. […] There appears to be no gender dominance in pilocytic astrocytomas. Study results have demonstrated a man-to-woman ratio of 1.18:1 in low-grade astrocytomas. In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as 1.87:1. […] The likelihood of pilocytic astrocytoma increases during the first 2 decades of life. Low-grade astrocytomas are predominant in individuals aged 30 to 40, comprising about one-fourth of adult cases. The age distribution of patients with low-grade astrocytomas is as follows: 10%: younger than 20, 60%: 20 to 45 years, 30%: older than 45 years. For grade 3 astrocytoma, the mean age at diagnosis is approximately 40 years.

• #26 Astrocytoma | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/17930

  The likelihood of pilocytic astrocytoma increases during the first 2 decades of life. […] Low-grade astrocytomas are predominant in individuals aged 30 to 40, comprising about one-fourth of adult cases. […] The age distribution of patients with low-grade astrocytomas is as follows: 10%: younger than 20, 60%: 20 to 45 years, 30%: older than 45 years. […] For grade 3 astrocytoma, the mean age at diagnosis is approximately 40 years.

• #27 Astrocytoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559042/

  Understanding epidemiological patterns for astrocytoma is important for identifying risk factors and improving early detection across various populations and age groups. […] Minimal racial differences have been found. […] There appears to be no gender dominance in pilocytic astrocytomas. Study results have demonstrated a man-to-woman ratio of 1.18:1 in low-grade astrocytomas. In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as 1.87:1. […] The likelihood of pilocytic astrocytoma increases during the first 2 decades of life. Low-grade astrocytomas are predominant in individuals aged 30 to 40, comprising about one-fourth of adult cases. The age distribution of patients with low-grade astrocytomas is as follows: 10%: younger than 20, 60%: 20 to 45 years, 30%: older than 45 years. For grade 3 astrocytoma, the mean age at diagnosis is approximately 40 years.

• #28 Astrocytoma, IDH-mutant | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/astrocytoma-idh-mutant-1?lang=us

  IDH-mutant adult-type astrocytomas are typically diagnosed in young adults (median age of 36 years for grades 2 and 3 (combined), and 38 years for grade 4). This is substantially younger than glioblastoma IDH-wildtype tumors (median 50-60 years of age). […] There is a substantially higher incidence in men of all ages and of all grades tumor (M:F ~1.5).

• #29 Astrocytoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Astrocytoma_epidemiology_and_demographics

  Anaplastic astrocytoma has an incidence of 0.49 per 100,000 per year. […] Glioblastoma has an incidence of 5 per 100,000 per year. […] Pilocytic astrocytoma accounts for 0.6 – 5.1% of all intracranial neoplasms (1.7-7% of all glial tumors) and are the most common primary brain tumor of childhood, accounting for 70-85% of all cerebellar astrocytomas. […] The median age of diffuse astrocytoma at the time of the diagnosis is 35 years, with a bimodal age distribution at 6 to 12 years and 26 to 46 years. […] Diffuse low grade gliomas of the cerebral hemispheres are typically diagnosed in young adults between 20-45 years old (mean 35 years of age). […] The peak incidence of glioblastoma is at ages 65 to 74 years.

• #30 Astrocytoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Astrocytoma_epidemiology_and_demographics

  Anaplastic astrocytoma has an incidence of 0.49 per 100,000 per year. […] Glioblastoma has an incidence of 5 per 100,000 per year. […] Pilocytic astrocytoma accounts for 0.6 – 5.1% of all intracranial neoplasms (1.7-7% of all glial tumors) and are the most common primary brain tumor of childhood, accounting for 70-85% of all cerebellar astrocytomas. […] The median age of diffuse astrocytoma at the time of the diagnosis is 35 years, with a bimodal age distribution at 6 to 12 years and 26 to 46 years. […] Diffuse low grade gliomas of the cerebral hemispheres are typically diagnosed in young adults between 20-45 years old (mean 35 years of age). […] The peak incidence of glioblastoma is at ages 65 to 74 years.

• #31 Astrocytoma – Diagnosis & Disease Information for HCPs

  https://www.cancertherapyadvisor.com/ddi/astrocytoma/

  In the United States, approximately 15,000 new cases of astrocytoma are diagnosed every year, accounting for roughly 50% of all brain tumors. The incidence of astrocytoma varies with the grade: grades I and II are less common, while high grades such as glioblastoma (grade IV) have a higher incidence and are associated with a worse prognosis. Astrocytoma tumors are slightly more common in males than in females. Higher-grade neoplasms are more common in adult patients, while low-grade forms occur more often in pediatric patients. […] The etiology of astrocytoma is complex; both genetic and environmental factors have a role in its pathogenesis. […] Risk factors for astrocytoma include the following: Occupational exposures to chemicals such as petrochemicals, formaldehyde, and polyvinyl chloride; Prolonged exposures to electromagnetic fields; and Exposure to pesticides and herbicides.

• #32 Astrocytoma – Diagnosis & Disease Information for HCPs

  https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/pediatrics/high-grade-astrocytomas/

  In the United States, approximately 15,000 new cases of astrocytoma are diagnosed every year, accounting for roughly 50% of all brain tumors. The incidence of astrocytoma varies with the grade: grades I and II are less common, while high grades such as glioblastoma (grade IV) have a higher incidence and are associated with a worse prognosis. Astrocytoma tumors are slightly more common in males than in females. Higher-grade neoplasms are more common in adult patients, while low-grade forms occur more often in pediatric patients. […] The etiology of astrocytoma is complex; both genetic and environmental factors have a role in its pathogenesis. […] Some of the environmental factors being investigated in relation to astrocytoma risk include occupational exposures to certain industrial chemicals, electromagnetic fields, pesticides, and certain dietary elements. […] Risk factors for astrocytoma include the following: Occupational exposures to chemicals such as petrochemicals, formaldehyde, and polyvinyl chloride; Prolonged exposures to electromagnetic fields; and Exposure to pesticides and herbicides.

• #33 Astrocytoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559042/

  Understanding epidemiological patterns for astrocytoma is important for identifying risk factors and improving early detection across various populations and age groups. […] Minimal racial differences have been found. […] There appears to be no gender dominance in pilocytic astrocytomas. Study results have demonstrated a man-to-woman ratio of 1.18:1 in low-grade astrocytomas. In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as 1.87:1. […] The likelihood of pilocytic astrocytoma increases during the first 2 decades of life. Low-grade astrocytomas are predominant in individuals aged 30 to 40, comprising about one-fourth of adult cases. The age distribution of patients with low-grade astrocytomas is as follows: 10%: younger than 20, 60%: 20 to 45 years, 30%: older than 45 years. For grade 3 astrocytoma, the mean age at diagnosis is approximately 40 years.

• #34 Astrocytoma | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/17930

  Astrocytomas represent a significant and complex subset of brain tumors originating from astrocytes, the star-shaped glial cells that play a critical role in supporting neuronal function within the cerebrum. […] These tumors present a considerable clinical challenge due to their prevalence and the serious morbidity and mortality they cause across all age groups. […] Understanding epidemiological patterns for astrocytoma is important for identifying risk factors and improving early detection across various populations and age groups. […] Minimal racial differences have been found. […] There appears to be no gender dominance in pilocytic astrocytomas. […] Study results have demonstrated a man-to-woman ratio of 1.18:1 in low-grade astrocytomas. […] In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as 1.87:1.

• #35 Astrocytoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Astrocytoma_epidemiology_and_demographics

  The incidence of astrocytoma is 0.23 per 100,000 and the number of new cases is 700 per year. […] In 2012, there were an estimated 148,818 people living with brain and other nervous system cancer in the United States. […] The number of deaths was 4.3 per 100,000 individuals per year based on 2008-2012 mortality records. […] The low-grade type is often found in children or young adults, while the high-grade type is more prevalent in adults. […] Pilocytic astrocytoma is more common in men, who account for 62% of all cases. […] The male-to-female ratio of diffuse astrocytoma is 1.5:1 and for anaplastic astrocytoma is 1.8:1. […] Astrocytoma is more common in caucasian race. […] Diffuse astrocytoma has an incidence of 0.1 per 100,000, with 1500 to 1800 new cases per year in North America.

• #36 Low-Grade Astrocytoma: Background, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1156429-overview

  A study of the incidence of brain tumors in Europe concluded that of all glial tumors, the astrocytic subtype is the most common with a reported incidence of 4.8 cases per 100,000 people per year. […] Five-year survival after diagnosis of a non-malignant CNS tumor is 91.9%. […] However, due to the inherent differences in biology and natural history of this heterogeneous patient population, it is difficult to determine an exact mortality rate for low-grade astrocytomas. […] Pilocytic tumors can potentially be cured with surgical resection, and in specific cases where resection is not amenable, these can be treated with BRAF inhibitors. […] Although survival is affected by some prognostic factors, average overall survival from diagnosis is about 56 years, ranging from 3 to 10 years. […] For primary tumors in the CNS, there is a slight increase in incidence in non-Hispanic patients (25.24 per 100,000 patients) compared to Hispanic patients (22.61 per 100,000 patients).

• #37 Astrocytoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/283453-overview

  The American Cancer Society estimates that in 2024, approximately 25,400 malignant tumors of the brain or spinal cord will be diagnosed, and about 18,760 deaths will occur from those tumors. […] The annual incidence of glioma in the United States is 6.0 cases per 100,000 population. […] In an analysis of the Central Brain Tumor Registry of the United States (CBTRUS) from 2019, 19% of all adult-type diffuse gliomas were IDH1-mutant astrocytomas. […] While increasing age has been shown to be a very strong risk factor for the development of glioblastoma, IDH1-mutant gliomas tend to affect a younger population. […] In the United States, the incidence of adult-type diffuse glioma is the highest in the non-Hispanic White population. […] A slight male predominance, with a male-to-female ratio of 1.18:1, has been reported for development of lower-grade astrocytomas. […] A more significant male predominance, with a male-to-female ratio of 1.87:1, has been reported for the development of higher-grade astrocytomas.

• #38 A comprehensive epidemiological review of spinal astrocytomas in the United States in: Journal of Neurosurgery: Spine Volume 34 Issue 2 (2020) Journals

  https://thejns.org/spine/view/journals/j-neurosurg-spine/34/2/article-p303.xml

  Spinal cord astrocytoma (SCA) is a rare tumor whose epidemiology has not been well defined. The authors utilized the Central Brain Tumor Registry of the United States (CBTRUS) to provide comprehensive up-to-date epidemiological data for this disease. […] Two thousand nine hundred sixty-nine SCAs were diagnosed in the US between 1995 and 2016, resulting in an average of approximately 136 SCAs annually. The overall AAI was 0.047 (95% CI 0.0450.049), and there was a statistically significant increase from 0.051 in 1995 to 0.043 in 2016. The peak incidence of 0.064 (95% CI 0.0600.067) was found in the 0- to 19-year age group. […] SCA incidence was significantly lower both in patients of Asian/Pacific Islander race (AAI = 0.034, 95% CI 0.0280.042, p = 0.00015) and in patients of Hispanic ethnicity (AAI = 0.035, 95% CI 0.0310.039, p 0.001).

• #39 Astrocytoma – Diagnosis & Disease Information for HCPs

  https://www.cancertherapyadvisor.com/ddi/astrocytoma/

  In the United States, approximately 15,000 new cases of astrocytoma are diagnosed every year, accounting for roughly 50% of all brain tumors. The incidence of astrocytoma varies with the grade: grades I and II are less common, while high grades such as glioblastoma (grade IV) have a higher incidence and are associated with a worse prognosis. Astrocytoma tumors are slightly more common in males than in females. Higher-grade neoplasms are more common in adult patients, while low-grade forms occur more often in pediatric patients. […] The etiology of astrocytoma is complex; both genetic and environmental factors have a role in its pathogenesis. […] Risk factors for astrocytoma include the following: Occupational exposures to chemicals such as petrochemicals, formaldehyde, and polyvinyl chloride; Prolonged exposures to electromagnetic fields; and Exposure to pesticides and herbicides.

• #40 Astrocytoma – Diagnosis & Disease Information for HCPs

  https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/pediatrics/high-grade-astrocytomas/

  In the United States, approximately 15,000 new cases of astrocytoma are diagnosed every year, accounting for roughly 50% of all brain tumors. The incidence of astrocytoma varies with the grade: grades I and II are less common, while high grades such as glioblastoma (grade IV) have a higher incidence and are associated with a worse prognosis. Astrocytoma tumors are slightly more common in males than in females. Higher-grade neoplasms are more common in adult patients, while low-grade forms occur more often in pediatric patients. […] The etiology of astrocytoma is complex; both genetic and environmental factors have a role in its pathogenesis. […] Some of the environmental factors being investigated in relation to astrocytoma risk include occupational exposures to certain industrial chemicals, electromagnetic fields, pesticides, and certain dietary elements. […] Risk factors for astrocytoma include the following: Occupational exposures to chemicals such as petrochemicals, formaldehyde, and polyvinyl chloride; Prolonged exposures to electromagnetic fields; and Exposure to pesticides and herbicides.

• #41 Low-Grade Astrocytoma: Background, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1156429-overview

  The overall incidence of all primary malignant and non-malignant brain and other CNS tumors is 24.83 cases per 100,000 people (6.94 per 100,000 for malignant tumors and 17.88 per 100,000 for non-malignant tumors). […] Of all glioma subtypes, diffuse astrocytomas represent 9.1% and pilocytic astrocytomas 5.1%. […] Although these numbers represent an approximate estimation of the epidemiology of low-grade astrocytomas, it is important to note that there are no studies that have addressed this group in an isolated fashion. […] Gliomas can be found more frequently in patients with certain phakomatoses, especially neurofibromatosis type 1 (NF-1). Low-grade astrocytomas occur more commonly in these patients, particularly in the optic nerves and optic chiasm. […] The incidence of low-grade astrocytomas has not been shown to vary significantly by nationality.

• #42 Pilocytic astrocytoma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/pilocytic-astrocytoma?lang=us

  Pilocytic astrocytomas are tumors of young people, with ~70% occurring in the first two decades of life, typically late in the first decade (9-10 years). […] Although they account for ~2.5% (range 0.6-5.1%) of all intracranial neoplasms (~4% of all glial tumors), they are the most common primary brain tumor of childhood (~15%) and the second most common pediatric posterior fossa tumor (~30%) after medulloblastomas. […] There is a strong association with NF1. NF1-associated tumors have a tendency to affect the optic nerves and chiasm (see: optic pathway glioma). The association between NF1 and pilocytic astrocytomas is so strong that up to 20% of all patients with NF1 will develop these tumors, typically in early childhood. Conversely, approximately one-third of pilocytic astrocytomas involving the optic nerves have associated NF1. […] Adults have a poorer prognosis, with a ~50% 5-year survival.

• #43 Glioblastoma Multiforme – AANS

  https://www.aans.org/patients/conditions-treatments/glioblastoma-multiforme/

  Glioblastoma is the most common malignant brain and other CNS tumors accounting for 47.7% of all cases. Glioblastoma has an incidence of 3.21 per 100,000 population. […] Median age of diagnosis is 64 years and it is more common in men as compared to women. Survival is poor with approximately 40% survival in the first year post diagnosis and 17% in the second year. […] Factors associated with glioblastoma risk are prior therapeutic radiation, decreased susceptibility to allergy and impaired immune response. Several hereditary cancer syndromes greatly increase the risk of glioblastoma, including Li-fraumeni syndrome and Lynch syndrome.

• #44 Astrocytoma – Diagnosis & Disease Information for HCPs

  https://www.cancertherapyadvisor.com/ddi/astrocytoma/

  In the United States, approximately 15,000 new cases of astrocytoma are diagnosed every year, accounting for roughly 50% of all brain tumors. The incidence of astrocytoma varies with the grade: grades I and II are less common, while high grades such as glioblastoma (grade IV) have a higher incidence and are associated with a worse prognosis. Astrocytoma tumors are slightly more common in males than in females. Higher-grade neoplasms are more common in adult patients, while low-grade forms occur more often in pediatric patients. […] The etiology of astrocytoma is complex; both genetic and environmental factors have a role in its pathogenesis. […] Risk factors for astrocytoma include the following: Occupational exposures to chemicals such as petrochemicals, formaldehyde, and polyvinyl chloride; Prolonged exposures to electromagnetic fields; and Exposure to pesticides and herbicides.

• #45 Astrocytoma – Diagnosis & Disease Information for HCPs

  https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/pediatrics/high-grade-astrocytomas/

  In the United States, approximately 15,000 new cases of astrocytoma are diagnosed every year, accounting for roughly 50% of all brain tumors. The incidence of astrocytoma varies with the grade: grades I and II are less common, while high grades such as glioblastoma (grade IV) have a higher incidence and are associated with a worse prognosis. Astrocytoma tumors are slightly more common in males than in females. Higher-grade neoplasms are more common in adult patients, while low-grade forms occur more often in pediatric patients. […] The etiology of astrocytoma is complex; both genetic and environmental factors have a role in its pathogenesis. […] Some of the environmental factors being investigated in relation to astrocytoma risk include occupational exposures to certain industrial chemicals, electromagnetic fields, pesticides, and certain dietary elements. […] Risk factors for astrocytoma include the following: Occupational exposures to chemicals such as petrochemicals, formaldehyde, and polyvinyl chloride; Prolonged exposures to electromagnetic fields; and Exposure to pesticides and herbicides.

• #46 Glioblastoma Multiforme – AANS

  https://www.aans.org/patients/conditions-treatments/glioblastoma-multiforme/

  Glioblastoma is the most common malignant brain and other CNS tumors accounting for 47.7% of all cases. Glioblastoma has an incidence of 3.21 per 100,000 population. […] Median age of diagnosis is 64 years and it is more common in men as compared to women. Survival is poor with approximately 40% survival in the first year post diagnosis and 17% in the second year. […] Factors associated with glioblastoma risk are prior therapeutic radiation, decreased susceptibility to allergy and impaired immune response. Several hereditary cancer syndromes greatly increase the risk of glioblastoma, including Li-fraumeni syndrome and Lynch syndrome.

• #47 Astrocytoma Tumors – AANS

  https://www.aans.org/patients/conditions-treatments/astrocytoma-tumors/

  Astrocytomas are tumors which originates from astrocytes, and, in adult individuals, they are the most common brain tumors. In the US, about 15,000 new astrocytomas are diagnosed every year. Males are slightly more affected than females, with a ratio of 1.3/1. […] Astrocytomas are, for the vast majority, sporadic tumors, meaning that they happen by chance, or at least, it is not yet known why these occur. There are only two situations with proven evidence to cause the tumor: […] The major factors determining length of survival after a diagnosis of astrocytoma are the following: […] Grade 1 tumors are largely cured (96% survival rate at 5 years), usually by surgery only. […] Grade 2 tumors: Overall median survival is 8 years. Presence of IDH1 mutation is associated with longer survival. […] Grade 3 tumors: Median survival is 3-5 years […] Grade 4 tumors: Median survival is 15 months.

• #48 Astrocytoma Tumors – AANS

  https://www.aans.org/patients/conditions-treatments/astrocytoma-tumors/

  Astrocytomas are tumors which originates from astrocytes, and, in adult individuals, they are the most common brain tumors. In the US, about 15,000 new astrocytomas are diagnosed every year. Males are slightly more affected than females, with a ratio of 1.3/1. […] Astrocytomas are, for the vast majority, sporadic tumors, meaning that they happen by chance, or at least, it is not yet known why these occur. There are only two situations with proven evidence to cause the tumor: […] The major factors determining length of survival after a diagnosis of astrocytoma are the following: […] Grade 1 tumors are largely cured (96% survival rate at 5 years), usually by surgery only. […] Grade 2 tumors: Overall median survival is 8 years. Presence of IDH1 mutation is associated with longer survival. […] Grade 3 tumors: Median survival is 3-5 years […] Grade 4 tumors: Median survival is 15 months.

• #49 Astrocytoma Tumors – AANS

  https://www.aans.org/patients/conditions-treatments/astrocytoma-tumors/

  Astrocytomas are tumors which originates from astrocytes, and, in adult individuals, they are the most common brain tumors. In the US, about 15,000 new astrocytomas are diagnosed every year. Males are slightly more affected than females, with a ratio of 1.3/1. […] Astrocytomas are, for the vast majority, sporadic tumors, meaning that they happen by chance, or at least, it is not yet known why these occur. There are only two situations with proven evidence to cause the tumor: […] The major factors determining length of survival after a diagnosis of astrocytoma are the following: […] Grade 1 tumors are largely cured (96% survival rate at 5 years), usually by surgery only. […] Grade 2 tumors: Overall median survival is 8 years. Presence of IDH1 mutation is associated with longer survival. […] Grade 3 tumors: Median survival is 3-5 years […] Grade 4 tumors: Median survival is 15 months.

• #50

  https://link.springer.com/article/10.1007/s11060-012-0829-0

  Pilocytic astrocytoma is a WHO grade 1 brain tumor common in children. […] Patients diagnosed with pilocytic astrocytoma between 1973 and 2008 were identified in the National Cancer Institute Surveillance, Epidemiology, and End Results Program database. […] Survival rates declined significantly with age, from 96.5% 60-month survival in patients 5-19 years (95% CI 95.3-97.4) to 52.9% 60-month survival in adult patients 60+ years of age (95% CI 38.4-65.5), with a corresponding decrease in relative and cancer-specific survival rates. […] Pilocytic astrocytoma is associated with higher mortality in adult patients than in children and teens, and survival decreases with increasing age in adults. […] The morbidity of pilocytic astrocytoma in adults provides rationale for future trials of adjuvant treatment in high-risk patients.

• #51 < ?php wp_title( '|', true, 'right' ); ?>

  https://surgicalneurologyint.com/surgicalint-articles/recurrent-adult-pilocytic-astrocytoma-presenting-with-intraventricular-and-leptomeningeal-spread/

  Several studies have shown that increasing patient age is correlated with lower rates of overall survival in pilocytic astrocytomas with 5-year survival dropping from 96.5% in pediatric patients to approximately 53% in patients older than 60. […] Furthermore, APAs appear to have increased recurrence rates and higher potential to undergo malignant transformation. […] However, postsurgical management of APAs, including adjuvant treatments for subtotal resections and surveillance imaging to identify tumor progression/ recurrence, remains controversial. […] If we adapt these findings to APAs, which are known to have higher recurrence rates and less favorable prognoses than their pediatric counterparts, then it may be beneficial to obtain more frequent interval imaging within the first few years after resection and continue to follow these patients long-term, especially in those with known subtotal resections.

• #52 Astrocytoma Tumors – AANS

  https://www.aans.org/patients/conditions-treatments/astrocytoma-tumors/

  Astrocytomas are tumors which originates from astrocytes, and, in adult individuals, they are the most common brain tumors. In the US, about 15,000 new astrocytomas are diagnosed every year. Males are slightly more affected than females, with a ratio of 1.3/1. […] Astrocytomas are, for the vast majority, sporadic tumors, meaning that they happen by chance, or at least, it is not yet known why these occur. There are only two situations with proven evidence to cause the tumor: […] The major factors determining length of survival after a diagnosis of astrocytoma are the following: […] Grade 1 tumors are largely cured (96% survival rate at 5 years), usually by surgery only. […] Grade 2 tumors: Overall median survival is 8 years. Presence of IDH1 mutation is associated with longer survival. […] Grade 3 tumors: Median survival is 3-5 years […] Grade 4 tumors: Median survival is 15 months.

• #53 Astrocytoma Tumors – AANS

  https://www.aans.org/patients/conditions-treatments/astrocytoma-tumors/

  Astrocytomas are tumors which originates from astrocytes, and, in adult individuals, they are the most common brain tumors. In the US, about 15,000 new astrocytomas are diagnosed every year. Males are slightly more affected than females, with a ratio of 1.3/1. […] Astrocytomas are, for the vast majority, sporadic tumors, meaning that they happen by chance, or at least, it is not yet known why these occur. There are only two situations with proven evidence to cause the tumor: […] The major factors determining length of survival after a diagnosis of astrocytoma are the following: […] Grade 1 tumors are largely cured (96% survival rate at 5 years), usually by surgery only. […] Grade 2 tumors: Overall median survival is 8 years. Presence of IDH1 mutation is associated with longer survival. […] Grade 3 tumors: Median survival is 3-5 years […] Grade 4 tumors: Median survival is 15 months.

• #54 Anaplastic astrocytoma – Wikipedia

  https://en.wikipedia.org/wiki/Anaplastic_astrocytoma

  Anaplastic astrocytoma is a rare WHO grade III type of astrocytoma, which is a type of cancer of the brain. In the United States, the annual incidence rate for anaplastic astrocytoma is 0.44 per 100,000 people. […] The age-standardized 5-year relative survival rate is 23.6%. Patients with this tumor are 46 times more likely to die than matched members of the general population. […] Typical median survival for anaplastic astrocytoma is 23 years. Secondary progression to glioblastoma multiforme is common. Radiation, younger age, female sex, treatment after 2000, and surgery were associated with improved survival in AA patients.

• #55 Anaplastic Astrocytoma Market Size, Share & Analysis, 2034

  https://www.imarcgroup.com/anaplastic-astrocytoma-market

  The anaplastic astrocytoma market has been comprehensively analyzed in IMARC’s new report titled „Anaplastic Astrocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. […] Anaplastic astrocytomas are quite rare, accounting for only 1-2% of all primary brain tumors. […] In the U.S., the annual incidence rate for anaplastic astrocytoma is 0.44 per 100,000 people. […] The age-standardized 5-year relative survival rate is 23.6 percent. […] The typical median survival time for anaplastic astrocytoma is 2-3 years. […] Anaplastic astrocytoma affects men slightly more than women, with a reported male-to-female incidence ratio of 1.87:1. […] IMARC Group’s new report provides an exhaustive analysis of the anaplastic astrocytoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. […] According to the report, the United States has the largest patient pool for anaplastic astrocytoma and also represents the largest market for its treatment. […] The report also provides the current and future patient pool across the seven major markets.

• #56 Astrocytoma Tumors – AANS

  https://www.aans.org/patients/conditions-treatments/astrocytoma-tumors/

  Astrocytomas are tumors which originates from astrocytes, and, in adult individuals, they are the most common brain tumors. In the US, about 15,000 new astrocytomas are diagnosed every year. Males are slightly more affected than females, with a ratio of 1.3/1. […] Astrocytomas are, for the vast majority, sporadic tumors, meaning that they happen by chance, or at least, it is not yet known why these occur. There are only two situations with proven evidence to cause the tumor: […] The major factors determining length of survival after a diagnosis of astrocytoma are the following: […] Grade 1 tumors are largely cured (96% survival rate at 5 years), usually by surgery only. […] Grade 2 tumors: Overall median survival is 8 years. Presence of IDH1 mutation is associated with longer survival. […] Grade 3 tumors: Median survival is 3-5 years […] Grade 4 tumors: Median survival is 15 months.

• #57 Adult intradural intramedullary astrocytomas: a multicenter analysis – Khalid – Journal of Spine Surgery

  https://jss.amegroups.org/article/view/4400/html

  Intramedullary tumors constitute approximately 2030% of all spinal cord tumors and approximately 3040% of these are astrocytomas. […] Due to their rarity and poor prognosis, large population-based studies are needed to assess the epidemiology and survival risk factors associated with these tumors in the hope of improving outcomes. […] This study suggest that older age, higher WHO grade, tumor invasiveness as well as sub-total resection were all associated with a worse prognosis. […] There is a paucity of studies assessing the long-term survival outcomes of adult patients with these neoplasms. […] Overall survival of these patients at 1 year, 3 years, 5 years and 10 years, were found to be 85.5%, 71.0%, 64.1%, and 55.0% respectively. […] Age at diagnosis (P=0.001), tumors of grade IV (P=0.000), invasive tumor extension (P=0.047), biopsy alone (P=0.016) and sub-total resection (P=0.029) were each associated with decreased survival and worse long-term prognosis.

• #58 Adult intradural intramedullary astrocytomas: a multicenter analysis – Khalid – Journal of Spine Surgery

  https://jss.amegroups.org/article/view/4400/html

  Intramedullary tumors constitute approximately 2030% of all spinal cord tumors and approximately 3040% of these are astrocytomas. […] Due to their rarity and poor prognosis, large population-based studies are needed to assess the epidemiology and survival risk factors associated with these tumors in the hope of improving outcomes. […] This study suggest that older age, higher WHO grade, tumor invasiveness as well as sub-total resection were all associated with a worse prognosis. […] There is a paucity of studies assessing the long-term survival outcomes of adult patients with these neoplasms. […] Overall survival of these patients at 1 year, 3 years, 5 years and 10 years, were found to be 85.5%, 71.0%, 64.1%, and 55.0% respectively. […] Age at diagnosis (P=0.001), tumors of grade IV (P=0.000), invasive tumor extension (P=0.047), biopsy alone (P=0.016) and sub-total resection (P=0.029) were each associated with decreased survival and worse long-term prognosis.

• #59 Adult intradural intramedullary astrocytomas: a multicenter analysis – Khalid – Journal of Spine Surgery

  https://jss.amegroups.org/article/view/4400/html

  The overall survival seen in this study is consistent with what previous literature has reported. […] Spinal cord neoplasms are relatively uncommon, accounting for approximately 1,7002,700 of the more than 17,000 newly diagnosed primary CNS lesions in the United States each year. […] The extension of a tumor into a neighboring or distant location of the body can profoundly impact the prognosis of the patient. […] While surgical intervention continues to be the mainstay treatment for intramedullary tumors, advancements in radiation and chemotherapy have expanded the therapy options for clinicians and offer patients an alternative choice to surgery. […] Age also seems to have a significant role in the prognosis of intramedullary astrocytoma patients with older individuals showing worse outcomes compared to their younger counterparts. […] Our study of 131 adult patients with intramedullary spinal cord astrocytomas provides insight into factors that may influence survival. Higher WHO tumors, age at diagnosis, tumor invasiveness, and sub-total resection appear to have significant associations with worse prognoses.

• #60 Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9248400/

  With improved outcome following aggressive treatment in patients with grade 2 and 3 IDH-mutant (IDHmt), 1p/19q codeleted oligodendroglioma and IDHmt, non-codeleted astrocytoma, prolonged surveillance is desirable for early detection of tumor growth and malignant transformation. […] Current National Comprehensive Cancer Network (NCCN) guidelines provide imaging follow-up recommendations based on molecular classification of lower-grade gliomas, although individualized imaging guidelines based on treatments received and after tumor recurrence are not clearly specified. […] The aim of surveillance after initial diagnosis and treatment, as well as after treatment for recurrent or progressive tumor, is to detect tumor growth or malignant transformation before symptoms develop and neurological function is irreparably compromised.

• #61 Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9248400/

  With improved outcome following aggressive treatment in patients with grade 2 and 3 IDH-mutant (IDHmt), 1p/19q codeleted oligodendroglioma and IDHmt, non-codeleted astrocytoma, prolonged surveillance is desirable for early detection of tumor growth and malignant transformation. […] Current National Comprehensive Cancer Network (NCCN) guidelines provide imaging follow-up recommendations based on molecular classification of lower-grade gliomas, although individualized imaging guidelines based on treatments received and after tumor recurrence are not clearly specified. […] The aim of surveillance after initial diagnosis and treatment, as well as after treatment for recurrent or progressive tumor, is to detect tumor growth or malignant transformation before symptoms develop and neurological function is irreparably compromised.

• #62 Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9248400/

  To date, the optimal frequency and serial imaging follow-up studies for LrGG are not well-defined. […] National Comprehensive Cancer Network (NCCN) guidelines advocate follow-up MRI every 36 months for 5 years then at least every 612 months or as clinically indicated thereafter for grade 2 glioma. […] For grade 3 glioma, MRI every 24 months for 3 years then every 36 months indefinitely is the recommendation. […] Consequently, the clinicians ability to order MRIs believed clinically indicated is sometimes administratively constrained. […] The determination of the optimal timing of surveillance to maximize detection while minimizing unnecessary, uninformative imaging studies requires analysis of available data on the time and pattern of relapse as well as the risk factors associated with early recurrence.

• #63 Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9248400/

  To date, the optimal frequency and serial imaging follow-up studies for LrGG are not well-defined. […] National Comprehensive Cancer Network (NCCN) guidelines advocate follow-up MRI every 36 months for 5 years then at least every 612 months or as clinically indicated thereafter for grade 2 glioma. […] For grade 3 glioma, MRI every 24 months for 3 years then every 36 months indefinitely is the recommendation. […] Consequently, the clinicians ability to order MRIs believed clinically indicated is sometimes administratively constrained. […] The determination of the optimal timing of surveillance to maximize detection while minimizing unnecessary, uninformative imaging studies requires analysis of available data on the time and pattern of relapse as well as the risk factors associated with early recurrence.

• #64 Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9248400/

  To date, the optimal frequency and serial imaging follow-up studies for LrGG are not well-defined. […] National Comprehensive Cancer Network (NCCN) guidelines advocate follow-up MRI every 36 months for 5 years then at least every 612 months or as clinically indicated thereafter for grade 2 glioma. […] For grade 3 glioma, MRI every 24 months for 3 years then every 36 months indefinitely is the recommendation. […] Consequently, the clinicians ability to order MRIs believed clinically indicated is sometimes administratively constrained. […] The determination of the optimal timing of surveillance to maximize detection while minimizing unnecessary, uninformative imaging studies requires analysis of available data on the time and pattern of relapse as well as the risk factors associated with early recurrence.

• #65 Astrocytoma (Adult-type) – American Brain Tumor Association | Learn More

  https://www.abta.org/tumor_types/astrocytoma/

  Astrocytomas are estimated to account for 3.5% of all primary brain tumors with approximately 1,500 new diagnoses in the United States each year. […] Diffuse astrocytomas most often occur between the ages of 20-60 with a median age at diagnosis of 46 years for lower grade lesions and 54 years for higher grade lesions. […] Although these tumors are found in both men and women, they tend to occur more often in men. […] Regular MRI scans are recommended following the diagnosis of astrocytoma, generally at least once per year.

• #66 Astrocytoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/brain-and-spinal-cord-childhood/treatment/astrocytoma

  Astrocytoma is a type of tumour that can develop in the brain and spinal cord. It starts in the astrocytes of the central nervous system (CNS). Astrocytomas are found in the cerebellum, cerebrum, central areas of the brain, brain stem and spinal cord. […] Astrocytomas can be classified as low or high grade, depending on how the tumour cells look and how quickly they grow and spread. […] Low-grade astrocytomas are generally treated with surgery, chemotherapy, radiation therapy, targeted therapy or a combination of these treatments. […] If the tumour is not completely removed, other treatments may be offered such as active surveillance, chemotherapy, radiation therapy or targeted therapy. […] Active surveillance involves watching the tumour with regular tests and exams to check if it is growing or causing symptoms. Active surveillance may be used for some low-grade astrocytomas.

• #67 Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9248400/

  The primary purpose of this manuscript is to review the current data and propose recommendations regarding the optimal frequency for a longitudinal imaging study of IDHmt grade 2 and 3 gliomas, acknowledging that the absence of prospective studies and limitations of existing data limit the level of evidence to expert opinion. […] Evidence supports a nonlinear growth rate pattern of grade 2 gliomas, with a significant increase in tumor growth in the final 6 months before malignant transformation. […] These data demonstrate that PFS shortens over time in IDHmt gliomas following first recurrence warranting even closer radiographic monitoring after first tumor progression than following initial diagnosis.

• #68 Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9248400/

  The primary purpose of this manuscript is to review the current data and propose recommendations regarding the optimal frequency for a longitudinal imaging study of IDHmt grade 2 and 3 gliomas, acknowledging that the absence of prospective studies and limitations of existing data limit the level of evidence to expert opinion. […] Evidence supports a nonlinear growth rate pattern of grade 2 gliomas, with a significant increase in tumor growth in the final 6 months before malignant transformation. […] These data demonstrate that PFS shortens over time in IDHmt gliomas following first recurrence warranting even closer radiographic monitoring after first tumor progression than following initial diagnosis.

• #69 < ?php wp_title( '|', true, 'right' ); ?>

  https://surgicalneurologyint.com/surgicalint-articles/recurrent-adult-pilocytic-astrocytoma-presenting-with-intraventricular-and-leptomeningeal-spread/

  Several studies have shown that increasing patient age is correlated with lower rates of overall survival in pilocytic astrocytomas with 5-year survival dropping from 96.5% in pediatric patients to approximately 53% in patients older than 60. […] Furthermore, APAs appear to have increased recurrence rates and higher potential to undergo malignant transformation. […] However, postsurgical management of APAs, including adjuvant treatments for subtotal resections and surveillance imaging to identify tumor progression/ recurrence, remains controversial. […] If we adapt these findings to APAs, which are known to have higher recurrence rates and less favorable prognoses than their pediatric counterparts, then it may be beneficial to obtain more frequent interval imaging within the first few years after resection and continue to follow these patients long-term, especially in those with known subtotal resections.

• #70 Postoperative Surveillance Magnetic Resonance Imaging for Cerebellar Astrocytoma | Canadian Journal of Neurological Sciences | Cambridge Core

  https://www.cambridge.org/core/journals/canadian-journal-of-neurological-sciences/article/postoperative-surveillance-magnetic-resonance-imaging-for-cerebellar-astrocytoma/05ECF8DA2A4B058B2FF4565AFF1584F2

  Patients with low grade astrocytomas generally have good prognosis when total resection can be achieved, but surveillance neuroimaging is commonly performed to detect recurrence or progression. […] This study illustrates pediatric patients with low-grade cerebellar astrocytomas undergoing total resection may not benefit from routine surveillance neuroimaging, primarily because of low recurrence likelihood. Patients with subtotal resection may benefit from surveillance of residual disease, with further work aimed at exploring the schedule of such follow-up.

• #71

  https://discovery.ucl.ac.uk/id/eprint/10119430/

  Surveillance imaging could be reduced in number and duration for completely resected cerebellar tumours. […] MDT decisions were rarely made on the basis of post-contrast imaging, and GBCA administration could therefore potentially be restricted in the setting of surveillance of grade 1 astrocytomas in children.

• #72

  https://discovery.ucl.ac.uk/id/eprint/10119430/

  Surveillance imaging could be reduced in number and duration for completely resected cerebellar tumours. […] MDT decisions were rarely made on the basis of post-contrast imaging, and GBCA administration could therefore potentially be restricted in the setting of surveillance of grade 1 astrocytomas in children.

• #73 Pilocytic astrocytoma epidemiology [Neurosurgery Education Wiki]

  https://neurosurgery.education/wiki/doku.php?id=pilocytic_astrocytoma_epidemiology

  The most common glioma in pediatrics (age 019 years) with an incidence of 0.82/100,000. […] Pilocytic astrocytoma, a WHO Grade I tumor, is the most common pediatric brain tumor between 5 and 14 years of age and the second most common in children younger than 5 and older than 14. […] Pilocytic astrocytoma is considered the most common subtype of pediatric intracranial tumor. […] The incidence progressively declines after age 15. Slight male predilection. Usually presents during second decade of life (ages 1020). 75% occur in age 20 years. […] They are rarely diagnosed in patients over the age of 18 years. […] In adults, these tumours appear more frequently supratentorially than in the cerebellum and some reports suggest a different clinical course in adults.

• #74 Pilocytic astrocytoma epidemiology [Neurosurgery Education Wiki]

  https://neurosurgery.education/wiki/doku.php?id=pilocytic_astrocytoma_epidemiology

  The most common glioma in pediatrics (age 019 years) with an incidence of 0.82/100,000. […] Pilocytic astrocytoma, a WHO Grade I tumor, is the most common pediatric brain tumor between 5 and 14 years of age and the second most common in children younger than 5 and older than 14. […] Pilocytic astrocytoma is considered the most common subtype of pediatric intracranial tumor. […] The incidence progressively declines after age 15. Slight male predilection. Usually presents during second decade of life (ages 1020). 75% occur in age 20 years. […] They are rarely diagnosed in patients over the age of 18 years. […] In adults, these tumours appear more frequently supratentorially than in the cerebellum and some reports suggest a different clinical course in adults.

• #75 Pilocytic astrocytoma epidemiology [Neurosurgery Education Wiki]

  https://neurosurgery.education/wiki/doku.php?id=pilocytic_astrocytoma_epidemiology

  The most common glioma in pediatrics (age 019 years) with an incidence of 0.82/100,000. […] Pilocytic astrocytoma, a WHO Grade I tumor, is the most common pediatric brain tumor between 5 and 14 years of age and the second most common in children younger than 5 and older than 14. […] Pilocytic astrocytoma is considered the most common subtype of pediatric intracranial tumor. […] The incidence progressively declines after age 15. Slight male predilection. Usually presents during second decade of life (ages 1020). 75% occur in age 20 years. […] They are rarely diagnosed in patients over the age of 18 years. […] In adults, these tumours appear more frequently supratentorially than in the cerebellum and some reports suggest a different clinical course in adults.

• #76 Pilocytic astrocytoma epidemiology [Neurosurgery Education Wiki]

  https://neurosurgery.education/wiki/doku.php?id=pilocytic_astrocytoma_epidemiology

  The most common glioma in pediatrics (age 019 years) with an incidence of 0.82/100,000. […] Pilocytic astrocytoma, a WHO Grade I tumor, is the most common pediatric brain tumor between 5 and 14 years of age and the second most common in children younger than 5 and older than 14. […] Pilocytic astrocytoma is considered the most common subtype of pediatric intracranial tumor. […] The incidence progressively declines after age 15. Slight male predilection. Usually presents during second decade of life (ages 1020). 75% occur in age 20 years. […] They are rarely diagnosed in patients over the age of 18 years. […] In adults, these tumours appear more frequently supratentorially than in the cerebellum and some reports suggest a different clinical course in adults.

• #77 Neuro-Ophthalmologic Manifestations of Pilomyxoid Astrocytoma (PMA) – EyeWiki

  https://eyewiki.org/Neuro-Ophthalmologic_Manifestations_of_Pilomyxoid_Astrocytoma_(PMA)

  JPA is the most common type of glioma in children and adolescents, accounting for approximately 15.6% of all brain tumors and 5.4% of all gliomas. […] In the United States, the annual incidence of PAs is approximately 0.35 – 0.37 per 100 persons. The highest incidence is found in children 0-9 years old and decreases with advancing age. […] PMA accounts for only 2.2% of all astrocytomas, but the true prevalence may be underestimated. […] Among the major differences between JPA and PMA is the age of patients and outcomes. PMA tends to affect infants and younger children, with a median age of 10 – 18 months. […] PMA has been noted to have a less favorable prognosis and patients are more likely to experience local recurrences and cerebrospinal spread than patients with PA. […] Due to rarity of PMA, the clinical data is limited to a small number of cases. Outcomes are improved for patients who underwent complete surgical excision. Age is also a strong prognostic factor for overall survival with infants and younger children (3 year) having worse outcomes.

• #78 Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma | UCSF Brain Tumor Center

  https://braintumorcenter.ucsf.edu/condition/diffuse-astrocytoma-grade-ii

  IDH-mutant astrocytomas are the second most common glioma, after glioblastoma, accounting for approximately 10-11% of all primary brain tumors. […] Most cases occur in adults, although they occasionally develop in children as well. […] Typically, complete surgical removal of the tumor visible on the MRI offers the best patient outcomes for long-term survival. However, IDH-mutant astrocytoma can recur after surgery, so patients are regularly monitored for both tumor recurrence and progression to a higher-grade tumor.

• #79 Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma | UCSF Brain Tumor Center

  https://braintumorcenter.ucsf.edu/condition/diffuse-astrocytoma-grade-ii

  IDH-mutant astrocytomas are the second most common glioma, after glioblastoma, accounting for approximately 10-11% of all primary brain tumors. […] Most cases occur in adults, although they occasionally develop in children as well. […] Typically, complete surgical removal of the tumor visible on the MRI offers the best patient outcomes for long-term survival. However, IDH-mutant astrocytoma can recur after surgery, so patients are regularly monitored for both tumor recurrence and progression to a higher-grade tumor.

• #80 Astrocytoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/283453-overview

  The American Cancer Society estimates that in 2024, approximately 25,400 malignant tumors of the brain or spinal cord will be diagnosed, and about 18,760 deaths will occur from those tumors. […] The annual incidence of glioma in the United States is 6.0 cases per 100,000 population. […] In an analysis of the Central Brain Tumor Registry of the United States (CBTRUS) from 2019, 19% of all adult-type diffuse gliomas were IDH1-mutant astrocytomas. […] While increasing age has been shown to be a very strong risk factor for the development of glioblastoma, IDH1-mutant gliomas tend to affect a younger population. […] In the United States, the incidence of adult-type diffuse glioma is the highest in the non-Hispanic White population. […] A slight male predominance, with a male-to-female ratio of 1.18:1, has been reported for development of lower-grade astrocytomas. […] A more significant male predominance, with a male-to-female ratio of 1.87:1, has been reported for the development of higher-grade astrocytomas.

• #81 Astrocytoma: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/283453-overview

  The American Cancer Society estimates that in 2024, approximately 25,400 malignant tumors of the brain or spinal cord will be diagnosed, and about 18,760 deaths will occur from those tumors. […] The annual incidence of glioma in the United States is 6.0 cases per 100,000 population. […] In an analysis of the Central Brain Tumor Registry of the United States (CBTRUS) from 2019, 19% of all adult-type diffuse gliomas were IDH1-mutant astrocytomas. […] While increasing age has been shown to be a very strong risk factor for the development of glioblastoma, IDH1-mutant gliomas tend to affect a younger population. […] In the United States, the incidence of adult-type diffuse glioma is the highest in the non-Hispanic White population. […] A slight male predominance, with a male-to-female ratio of 1.18:1, has been reported for development of lower-grade astrocytomas. […] A more significant male predominance, with a male-to-female ratio of 1.87:1, has been reported for the development of higher-grade astrocytomas.

• #82 Treatment and prognosis of IDH-mutant astrocytomas in adults – UpToDate

  https://www.uptodate.com/contents/treatment-and-prognosis-of-idh-mutant-astrocytomas-in-adults

  Diffuse astrocytomas represent the most common group of infiltrative primary brain tumors in adults. They exist on a spectrum of biologic aggressiveness, but all are incurable and the vast majority are life limiting. […] Since discovery of the importance of isocitrate dehydrogenase (IDH) mutations in the pathogenesis and prognosis of diffuse gliomas, classification of astrocytomas has evolved, and treatment decisions are now considered separately for IDH-mutant astrocytomas and IDH-wildtype astrocytomas (eg, glioblastoma). Across all grades, the presence of an IDH mutation identifies a group of tumors with a more prolonged natural history and favorable prognosis than that of IDH-wildtype tumors. […] Historically, management of patients with diffuse gliomas has been based on histologic subtype and tumor grade and informed by results from clinical trials in patients with both astrocytic and oligodendroglial tumors, carried out prior to the recognition of the molecular and prognostic differences among these tumors. In some cases, tumor specimens were later assessed for IDH and 1p/19q status and data reanalyzed according to the modern World Health Organization (WHO) classification. Going forward, trials are increasingly being aligned with integrated molecular tumor diagnoses rather than historical groupings of low-grade glioma and high-grade glioma. […] This topic will review the initial management of IDH-mutant astrocytomas, grades 2, 3, and 4.

• #83 A comprehensive epidemiological review of spinal astrocytomas in the United States in: Journal of Neurosurgery: Spine Volume 34 Issue 2 (2020) Journals

  https://thejns.org/spine/view/journals/j-neurosurg-spine/34/2/article-p303.xml

  Spinal cord astrocytoma (SCA) is a rare tumor whose epidemiology has not been well defined. The authors utilized the Central Brain Tumor Registry of the United States (CBTRUS) to provide comprehensive up-to-date epidemiological data for this disease. […] Two thousand nine hundred sixty-nine SCAs were diagnosed in the US between 1995 and 2016, resulting in an average of approximately 136 SCAs annually. The overall AAI was 0.047 (95% CI 0.0450.049), and there was a statistically significant increase from 0.051 in 1995 to 0.043 in 2016. The peak incidence of 0.064 (95% CI 0.0600.067) was found in the 0- to 19-year age group. […] SCA incidence was significantly lower both in patients of Asian/Pacific Islander race (AAI = 0.034, 95% CI 0.0280.042, p = 0.00015) and in patients of Hispanic ethnicity (AAI = 0.035, 95% CI 0.0310.039, p 0.001).

• #84 A comprehensive epidemiological review of spinal astrocytomas in the United States in: Journal of Neurosurgery: Spine Volume 34 Issue 2 (2020) Journals

  https://thejns.org/spine/view/journals/j-neurosurg-spine/34/2/article-p303.xml

  Spinal cord astrocytoma (SCA) is a rare tumor whose epidemiology has not been well defined. The authors utilized the Central Brain Tumor Registry of the United States (CBTRUS) to provide comprehensive up-to-date epidemiological data for this disease. […] Two thousand nine hundred sixty-nine SCAs were diagnosed in the US between 1995 and 2016, resulting in an average of approximately 136 SCAs annually. The overall AAI was 0.047 (95% CI 0.0450.049), and there was a statistically significant increase from 0.051 in 1995 to 0.043 in 2016. The peak incidence of 0.064 (95% CI 0.0600.067) was found in the 0- to 19-year age group. […] SCA incidence was significantly lower both in patients of Asian/Pacific Islander race (AAI = 0.034, 95% CI 0.0280.042, p = 0.00015) and in patients of Hispanic ethnicity (AAI = 0.035, 95% CI 0.0310.039, p 0.001).

• #85 Adult intradural intramedullary astrocytomas: a multicenter analysis – Khalid – Journal of Spine Surgery

  https://jss.amegroups.org/article/view/4400/html

  Intramedullary tumors constitute approximately 2030% of all spinal cord tumors and approximately 3040% of these are astrocytomas. […] Due to their rarity and poor prognosis, large population-based studies are needed to assess the epidemiology and survival risk factors associated with these tumors in the hope of improving outcomes. […] This study suggest that older age, higher WHO grade, tumor invasiveness as well as sub-total resection were all associated with a worse prognosis. […] There is a paucity of studies assessing the long-term survival outcomes of adult patients with these neoplasms. […] Overall survival of these patients at 1 year, 3 years, 5 years and 10 years, were found to be 85.5%, 71.0%, 64.1%, and 55.0% respectively. […] Age at diagnosis (P=0.001), tumors of grade IV (P=0.000), invasive tumor extension (P=0.047), biopsy alone (P=0.016) and sub-total resection (P=0.029) were each associated with decreased survival and worse long-term prognosis.

• #86 Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—through the looking glass! | Egyptian Journal of Neurosurgery | Full Text

  https://ejns.springeropen.com/articles/10.1186/s41984-021-00118-w

  Hospital-based cancer registries can provide information on the magnitude and distribution of cancers in a given hospital. […] Data were analyzed and compared with that of previously published literature, and inferences were drawn on patterns of reporting and epidemiology. […] Majority of cases (41.4%) were glioblastoma with the next common tumor (22.8%) being diffuse astrocytoma […] The exact prevalence of these tumors in developing countries, especially in India, is difficult to determine due to lack of data registry like CBTRUS. […] Understanding the trend helps caregivers in early detection and management of glioma. […] The referral pattern suggests an increasing prevalence of glioma patients in the last 12 years. […] The study also highlights increasing tumor burden in developing country since the last decade with the trend of early age presentation.

• #87 Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—through the looking glass! | Egyptian Journal of Neurosurgery | Full Text

  https://ejns.springeropen.com/articles/10.1186/s41984-021-00118-w

  Hospital-based cancer registries can provide information on the magnitude and distribution of cancers in a given hospital. […] Data were analyzed and compared with that of previously published literature, and inferences were drawn on patterns of reporting and epidemiology. […] Majority of cases (41.4%) were glioblastoma with the next common tumor (22.8%) being diffuse astrocytoma […] The exact prevalence of these tumors in developing countries, especially in India, is difficult to determine due to lack of data registry like CBTRUS. […] Understanding the trend helps caregivers in early detection and management of glioma. […] The referral pattern suggests an increasing prevalence of glioma patients in the last 12 years. […] The study also highlights increasing tumor burden in developing country since the last decade with the trend of early age presentation.

• #88 Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—through the looking glass! | Egyptian Journal of Neurosurgery | Full Text

  https://ejns.springeropen.com/articles/10.1186/s41984-021-00118-w

  Hospital-based cancer registries can provide information on the magnitude and distribution of cancers in a given hospital. […] Data were analyzed and compared with that of previously published literature, and inferences were drawn on patterns of reporting and epidemiology. […] Majority of cases (41.4%) were glioblastoma with the next common tumor (22.8%) being diffuse astrocytoma […] The exact prevalence of these tumors in developing countries, especially in India, is difficult to determine due to lack of data registry like CBTRUS. […] Understanding the trend helps caregivers in early detection and management of glioma. […] The referral pattern suggests an increasing prevalence of glioma patients in the last 12 years. […] The study also highlights increasing tumor burden in developing country since the last decade with the trend of early age presentation.

• #89 Orphanet: Astrocytoma

  https://www.orpha.net/en/disease/detail/94

  A complex group of benign and malignant cerebral tumors arising at any age. […] Prevalence: 1-9 / 100 000. […] They are the most frequent cerebral tumors and represent more than half of all primary brain tumors. Incidence is estimated at 1/12,500. […] Age at diagnosis may influence tumor biology and evolution; the outcome generally being better in children. […] The relative rarity of these tumors calls for the management of patients in prospective trials aimed at improving prognosis and quality of survival.

• #90 Astrocytoma Treatment Drug Market to Witness Upsurge in Growth During the Study Period (2020-2034) | DelveInsight

  https://www.prnewswire.com/news-releases/astrocytoma-treatment-drug-market-to-witness-upsurge-in-growth-during-the-study-period-20202034–delveinsight-302227405.html

  The astrocytoma epidemiology section provides insights into the historical and current astrocytoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. […] The astrocytoma market report proffers epidemiological analysis for the study period 20202034 in the 7MM segmented into: Total Incident Cases, Total Diagnosed Cases by Age Distribution, Grade-Specific Cases, Gender-specific Cases, Line-wise Treated Cases. […] The increasing prevalence of brain tumors, including astrocytomas, is a significant driver, leading to a higher demand for effective treatments. […] Advancements in diagnostic techniques, such as imaging technologies and biomarker identification, have improved early detection and accurate diagnosis, thereby propelling market growth.

• #91 Astrocytoma Treatment Drug Market to Witness Upsurge in Growth During the Study Period (2020-2034) | DelveInsight

  https://www.prnewswire.com/news-releases/astrocytoma-treatment-drug-market-to-witness-upsurge-in-growth-during-the-study-period-20202034–delveinsight-302227405.html

  The anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the astrocytoma market in the 7MM. […] Limited awareness and understanding of astrocytoma among both healthcare providers and patients also contribute to underdiagnosis and suboptimal treatment, hindering market growth. […] Moreover, the rarity of astrocytoma compared to other cancers can result in lower prioritization for research funding and pharmaceutical investment, limiting the availability of novel treatment options. […] Finally, reimbursement issues and variations in healthcare coverage can restrict patient access to advanced treatments, further exacerbating the market’s barriers.

Zobacz więcej